TNF and myeloid sarcoma: In a randomized phase 2 trial the TNF-inhibitor lenercept was tested for safety and efficacy in MS but had to be terminated prematurely after the interim analysis detected a dose-dependent increase in the frequency and severity of MS exacerbations75.